
Triptorelin, sold under the brand name Decapeptyl among others, is a medication that acts as an agonist analog of gonadotropin-releasing hormone, repressing expression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It was patented in 1975 and approved for medical use in 1986. Triptorelin is a therapeutic alternative on the World Health Organization's List of Essential Medicines.
It is a decapeptide (pGlu-His-Trp-Ser-Tyr--Trp-Leu-Arg-Pro-Gly-NH2) and a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts.
Primary indications include endometriosis, for the reduction of uterine fibroids, to treat prostate cancer, to treat male hypersexuality with severe sexual deviation, and to delay puberty in cases of precocious puberty or gender dysphoria.
Medical uses
Triptorelin is used to treat prostate cancer as part of androgen deprivation therapy.
Another common use in the United Kingdom is for hormone replacement therapy to suppress testosterone or estrogen levels in transgender people (in conjunction with estradiol valerate for trans women or testosterone for trans men). Spironolactone and cyproterone acetate are other drugs used by trans people to suppress sex hormones, but these drugs have a completely different mechanism of action. It can also be used as a puberty blocker in the case of precocious puberty.
Triptorelin has been used as a chemical castration agent for reducing sexual urges in sex offenders.
×